Compare DSY & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSY | IGC |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.9M | 33.8M |
| IPO Year | N/A | N/A |
| Metric | DSY | IGC |
|---|---|---|
| Price | $0.35 | $0.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 124.0K | ★ 435.0K |
| Earning Date | 01-01-0001 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.37 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $7,323,356.00 | $1,106,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | $28.97 | ★ N/A |
| Revenue Growth | ★ 16.37 | N/A |
| 52 Week Low | $0.32 | $0.25 |
| 52 Week High | $7.33 | $0.50 |
| Indicator | DSY | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 19.08 | 46.96 |
| Support Level | $0.32 | $0.28 |
| Resistance Level | $0.43 | $0.36 |
| Average True Range (ATR) | 0.02 | 0.02 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 21.87 | 58.97 |
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.